Emerging IL-12-based nanomedicine for cancer therapy

Zeyuan Xin,Shuai Qu,Yunfeng Qu,Yunxue Xu,Renfa Liu,Desheng Sun,Zhifei Dai
DOI: https://doi.org/10.1016/j.nantod.2024.102331
IF: 17.4
2024-06-02
Nano Today
Abstract:Interleukin-12 (IL-12), a powerful type 1 pro-inflammatory cytokine, demonstrates significant antitumor properties across numerous preclinical tumor models. However, the impressive antitumor efficacy demonstrated by IL-12 in preclinical studies has not been effectively reproduced in clinical researches. Clinical studies utilizing IL-12 as a treatment predominantly have shown limited efficacy in achieving sustained antitumor responses and are often accompanied by significant toxicities. Nevertheless, IL-12's pleiotropic antitumor activity still predicts a great promising future in cancer therapy, attracting enormous cancer researchers. Efforts are underway to enhance the local accumulation of IL-12 within the tumor microenvironment while minimizing systemic exposure. In preclinical studies, diverse IL-12 delivery systems, from fusion proteins to mRNA encapsulated in nanoparticles, have demonstrated robust antitumor effects with reduced toxicity. Several IL-12 delivery approaches have recently entered the clinical stage. In this review, we mainly discuss the development of nanomedicine-associated delivery mechanisms for IL-12 in cancer therapy, emphasizing advantageous approaches to harness IL-12's antitumor properties and mitigate its adverse side effects.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
What problem does this paper attempt to address?